VEGFA and cancer: VEGF‐A/VEGFR2 signalling has been targeted by a number of clinically approved inhibitors used to treat cancer, such as receptor TK inhibitors (RTKIs) that target the intracellular ATP‐binding domain (Ferrara & Adamis, 2016).